Flag of the European Union EU Clinical Trials Register Help

Clinical trials for International Classification of Headache Disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: International Classification of Headache Disorders. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-001968-28 Sponsor Protocol Number: 19385A Start Date*: 2022-02-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache
    Medical condition: Chronic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) FI (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003729-62 Sponsor Protocol Number: R-Verapamil-001 Start Date*: 2013-01-16
    Sponsor Name:CENTER LABORATORIES, INC
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache
    Medical condition: Episodic Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004835-23 Sponsor Protocol Number: TON/01/05-CLIN Start Date*: 2006-01-26
    Sponsor Name:Minster Pharmaceuticals Ltd
    Full Title: Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headache
    Medical condition: Migraine with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003148-21 Sponsor Protocol Number: BASICstudy Start Date*: 2019-01-25
    Sponsor Name:NTNU- Norwegian University of Science and Technology
    Full Title: BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache
    Medical condition: Chronic cluster headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006687-25 Sponsor Protocol Number: 79665 Start Date*: 2022-07-21
    Sponsor Name:Leiden University Medical Centre
    Full Title: Repeated corticosteroid injections around the Greater Occipital Nerve (GON) as prophylactic treatment in chronic cluster headache
    Medical condition: Chronic Cluster headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001882-17 Sponsor Protocol Number: I5Q-MC-CGAH Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine - the EVOLVE-2 Study
    Medical condition: Episodic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001707-36 Sponsor Protocol Number: 20120295 Start Date*: 2014-02-26
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
    Medical condition: Prevention of chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10027608 Migraine, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FI (Completed) DK (Completed) PL (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002331-28 Sponsor Protocol Number: 20190006 Start Date*: 2020-03-10
    Sponsor Name:Amgen Inc.
    Full Title: Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
    Medical condition: Episodic or chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2019-003646-33 Sponsor Protocol Number: 20190008 Start Date*: 2020-06-24
    Sponsor Name:Amgen, Inc.
    Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph...
    Medical condition: High frequency episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-004463-20 Sponsor Protocol Number: 20120297 Start Date*: 2015-10-02
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Medical condition: Migraine Prevention
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000210-21 Sponsor Protocol Number: TON/02/05-CLIN Start Date*: 2006-03-27
    Sponsor Name:Prof Jes Olesen
    Full Title: A single centre, double-blind, randomised, placebo controlled cross-over study to evaluate the efficacy and tolerability of tonabersat in the prophylaxis of migraine in patients presenting with mig...
    Medical condition: Migraine with aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001771-36 Sponsor Protocol Number: CHDR1755 Start Date*: 2019-07-16
    Sponsor Name:Centre for Human Drug Research
    Full Title: Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000079-31 Sponsor Protocol Number: 1246.4 Start Date*: 2008-07-16
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered oral...
    Medical condition: migraine headache with and without aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027602 Migraine headache LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) BE (Completed) SE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004378-24 Sponsor Protocol Number: H8H-MC-LAHV Start Date*: 2020-09-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Pediatric Options for Migraine Relief: A randomized, double-blind, placebo-controlled study of lasmiditan for acute treatment of migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) BE (Trial now transitioned) IT (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002866-38 Sponsor Protocol Number: FM-BOEM Start Date*: 2018-01-25
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
    Full Title: Pilot study for the evaluation of the efficacy of OnabotulinumtoxinA in high frequency migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002211-18 Sponsor Protocol Number: CAMG334A2301 Start Date*: 2016-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have fail...
    Medical condition: Migraine Prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SE (Completed) DE (Completed) FI (Completed) ES (Completed) AT (Completed) DK (Completed) BE (Completed) GR (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001175-14 Sponsor Protocol Number: BHV3000-406 Start Date*: 2023-04-17
    Sponsor Name:Biohaven Pharmaceuticals, Inc.
    Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
    Medical condition: migraine attacks with or without aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001884-38 Sponsor Protocol Number: I5Q-MC-CGAJ Start Date*: 2015-12-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine.
    Medical condition: Episodic or chronic migraine headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002348-28 Sponsor Protocol Number: 0462-083 Start Date*: 2011-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 11:26:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA